News | November 22, 2013

Hologic Showcases Newest Mammography Technology at RSNA 2013

mammography systems rsna 2013 women's health hologic 3-d 2-d
November 22, 2013 — Hologic Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products with an emphasis on serving the healthcare needs of women, announced the imaging products it will highlight at the Radiological Society of North America Annual Meeting (RSNA 2013) Dec. 1-5 in Chicago.
 
Hologic is dedicating a significant share of its RSNA exhibit to the clinical benefits of 3-D mammography in breast cancer screening and diagnosis as well as its recently introduced lower-dose 3-D mammography and 3-D guided breast biopsy capabilities.
 
Lower dose 3-D mammography
The C-View 2-D software option is designed to generate a 2-D image from a 3-D mammography data set without the need for separate 2-D X-ray exposures. C-View software is designed to offer radiologists and patients a number of benefits, including a reduction in X-ray exposures leading to shorter exam times (less than four second scans per view) and increased patient comfort from the shorter compression time. Hologic’s 3-D mammography exam using C-View software is a lower dose mammogram than the average U.S. 2-D mammogram, and yet it includes all the benefits of a combined 2-D and 3-D mammography exam.
 
3-D guided breast biopsy
The Affirm 3-D mammography biopsy option is designed for the localization and accurate targeting of regions of interest and is especially important for targeting lesions not detected in 2-D imaging or when using other modalities. This new biopsy technique is designed to provide numerous advantages over traditional stereotactic biopsy procedures, including faster lesion targeting and reduced patient procedure time. The Affirm system is preprogrammed for use with the Company's Eviva and ATEC vacuum-assisted breast biopsy devices. 
 
The Selenia Dimensions 3-D mammography system is currently the only U.S. Food and Drug Administration (FDA)-approved 3-D system in the United States, and Hologic is the only company worldwide that can provide a 3-D breast biopsy solution.
 
The 3-D mobile coach is making a special stop at RSNA on its yearlong, cross-country “3-D Technology: A More Accurate Mammogram” tour, which is dedicated to spreading the word about the important clinical benefits of 3-D mammography. 
Additionally, over 60 new scientific papers, poster sessions and sponsored courses will be presented at RSNA on 3-D mammography, many of which used Hologic’s 3-D technology. 
 
Other products:
  • The ImageChecker CAD 10.0 software for C-View 2-D images will be on display and available for demonstration at RSNA 2013. The CAD C-View 2-D software is currently in review with the FDA. 
  • Single Energy (SE) Femur Exam capability is exclusive for the Hologic Horizon DXA system for the assessment of features associated with atypical femur fracture (AFF). This capability assists clinicians in their identification of potential AFFs in patients who have been on anti-resorptive treatments such as bisphosphonates. The 15-second SE Femur Exam is designed to produce a high-resolution image of the entire femur with a very low effective radiation dose. The Horizon DXA system was launched in August and is designed to offer clinicians expanded technical capabilities, workflow efficiencies and improved design components that assist clinicians in the assessment of critical health problems: osteoporosis, cardiovascular disease, body composition and atypical femur fractures. 
  • MultiView MR software offers advanced options for Hologic’s MultiView platform software. Hologic’s MR software is designed to provide real-time 4-D (3-D plus time) image processing, speed, flexibility and dedicated magnetic resonance imaging (MRI) algorithms for both breast and prostate diagnostic viewing.
 
For more information: www.hologic.com, www.rsna.org

Related Content

Biop Medical Launches Cervical Cancer Diagnosis Technology at MEDICA 2017

Biop Medical cervical cancer detection system

Technology | Women's Health | November 13, 2017
November 13, 2017 — Biop Medical announced it will present its point-of-care...
Kansas City Radiology Center Employs iCAD PowerLook Tomo Detection for DBT
News | Computer-Aided Detection Software | November 10, 2017
November 10, 2017 — Imaging for Women, a leading radiology center in Kansas City, Mo., announced it is now using iCAD
Kubtec Brings Image Analytics Capabilities to Tomosynthesis Specimen Imaging Systems
News | Mammography | November 10, 2017
Kubtec announced it will be showcasing new image analytics capabilities on its advanced tomosynthesis specimen imaging...
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Imaging | November 10, 2017
November 10, 2017 — To address the specific needs of...
Fujifilm Highlights Women's Health and Pediatrics at RSNA 2017
News | Information Technology | November 08, 2017
November 8, 2017 — Fujifilm Healthcare will showcase a variety of imaging and information technology solutions at the
CureMetrix Expands Medical Advisory Board
News | Computer-Aided Detection Software | November 08, 2017
November 8, 2017 — CureMetrix, a company developing...
ICPME Makes EQUIP Mammography Inspection CME/CE Webinar Available Online
News | Mammography | November 08, 2017
November 8, 2017 — In conjunction with Brea...
Study Suggests Breast Cancer Patients Forego Post-Surgery Treatment Due to Mistrust
News | Radiation Therapy | November 06, 2017
November 6, 2017 — Nearly one-third of women with...
Study shows tissue marker reduces radiation target volumes, produces many other advantages

These CT images show placement of a 3-D fixed array implanted fiducial (3-D marker) at the time of oncoplastic tumor resection. The original LCTV (LCTVo) was retrospectively re-contoured by the radiation oncologist (LCTVro) and breast surgeon (LCTVbs). Thereafter, both re-contours were combined to create the collaborative LCTV (LCTVc), which required agreement of both the radiation oncologist and breast surgeon. Volume differences between the original LCTV (LCTVo) and the collaborative LCTVc were then evaluated, and demonstrated a mean and median reduction in LCTV.

Feature | Tumor Tracking Systems | November 06, 2017 | By William Hall, M.D.
Radiation planning for breast cancer relies on accurate delineation of the post-lumpectomy target volume as identified...
Blood Test Rules Out Breast Cancer Regardless of Density
News | Oncology Diagnostics | November 03, 2017
November 3, 2017 — A new study published in ...
Overlay Init